DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
M••••••• I•••••••••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Also written as: 11; 11/6/2025; 2025; 6; Equity
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
100¢ · 99¢ · 99¢ · 100¢ · 101¢Q2 2025 to Q2 2026
Principal held
at least $46.0M
sum of BDC pieces, a lower bound
Fair value
$48.7M
101c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Apr 1, 2030
no dated debt inside 24 months
On the tape since
Mar 31, 2025
latest Jun 30, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $46M | 101¢ | +1 pts |
Every BDC piece · 2 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, A•••• 2030, P•••• + 1.45%, F•••• rate 8.45%, 6.95% E••• Fee | $46.0M | $46.9M 101c | S+145 bp |
| H••••••• C••••••• I••• | equity equity C••••• S•••• | Not disclosed | $1.9M 186c |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $46.0M | 101c | S+145 bp | Apr 1, 2030 | 1 |
Equity pieces beside the debt: equity ($1.9M fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $46.0M | $46.9M | 101c | 0 |
| Mar 31, 2026 | 1 | $46.0M | $46.0M | 100c | 0 |
| Dec 31, 2025 | 1 | $34.5M | $34.2M | 99c | 0 |
| Sep 30, 2025 | 1 | $34.5M | $34.1M | 99c | 0 |
All 6 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $34.5M | $34.3M | 100c | 0 |
| Mar 31, 2025 | 1 | $57.0M | $56.4M | 100c | 0 |
What changed
- New borrower on a BDC scheduleMar 31, 2025
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- M••••••• I•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it